Brief: Transgene And BioInvent Announce Preclinical Data For BT-001

Transgene SA

11/12/2019 07:21

Dec 11 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE AND BIOINVENT ANNOUNCE COMPELLING PRECLINICAL
DATA FOR
BT-001 IN SOLID TUMORS
    * BT-001 IS A NOVEL INVIR.IO® BASED ONCOLYTIC VIRUS
EXPRESSING A
TREG-DEPLETING ANTI-CTLA4 ANTIBODY AND CYTOKINE GM-CSF
    * REGULATORY SUBMISSION FOR FIRST CLINICAL TRIAL IN EUROPE
AND US
IN H1 2020
    * BROAD ANTITUMOR ACTIVITY SHOWN IN IMMUNOCOMPETENT MODELS
SENSITIVE OR RESISTANT TO IMMUNE CHECKPOINT BLOCKADE
    * BIOINVENT AND TRANSGENE CONFIRM THAT THEY INTEND TO SUBMIT
CLINICAL TRIAL APPLICATION IN FIRST HALF OF 2020 TO CONDUCT
FIRST-IN-HUMAN TRIAL WITH BT-001 IN EUROPE AND IN USA
    * THE THERAPEUTIC ACTIVITY WAS ASSESSED IN SEVERAL
IMMUNOCOMPETENT
PRECLINICAL MODELS, SHOWING OUTSTANDING ANTITUMORAL ACTIVITY FOR
BT-001 MURINE SURROGATE ANTIBODY-ENCODING VIRUSES CONFERRING
CURES IN A MAJORITY OF MICE TRANSPLANTED WITH DIFFERENT SOLID
CANCER TUMORS (> 70% IN ALL TESTED MODELS)
    * NEW PRECLINICAL DATA ALSO CONFIRMED THAT ANTI-CTLA4
ANTIBODY
EXPRESSED BY BT-001 IN MOUSE TUMOR CELLS RETAINED BIOCHEMICAL
INTEGRITY AND FOLDING, FUNCTIONALITY, AND BIOLOGICAL ACTIVITY
    * BT-001’S BIODISTRIBUTION PROFILE DEMONSTRATED HIGHER
CONCENTRATION AND PROLONGED ACTIVITY OF THE ANTI-CTLA4
ANTIBODIES IN TUMORS COMPARED TO INTRAVENOUS ANTI-CTLA4 ANTIBODY
THERAPY

Source text for Eikon:  ID:nBwzJgnPa 
Further company coverage:  TRNG.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))